| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Korean Cancer Assoc > Volume 18(1); 1986 > Article
Journal of the Korean Cancer Association 1986;18(1): 35-41.
항암 화학요법시 발생한는 오심 , 구토의 조절
조성민, 장진원, 문한림, 홍영선, 김훈교, 김호연, 이경식, 김동집
Control of Cancer Chemotherapy-induced Nausea and Vomiting
Sung Min Cho, Jin Won Chang, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Ho Yun Kim, Kyung Shik Lee, Dong Jip Kim
ABSTRACT
Nausea and vomiting are very unpleasant side effects and can be severe enough to inte- rrupt patients to take nutrition and to delay or stop therapy. Authors tried two combinations of antiemetic regimen with different drugs. In the first group of patients who were treated with cis-platin containing drugs, high doses of metoclopramide, 100 mg intravenously 30 minutes before and 1. 5, 3. 5, 5.5, and 8. 5 hours after chemotherapy and dexamethasone 20 mg intravenously RO minutes before chemotherapy were given on the first day. On the second and third day, metoclopramide 100 mg were given I V every 6 hours with 20 mg of oral thiethylperazine per day. The response rate was 91%, 82% and 100% on day 1,2 and 3, In the second group of patients treated with adriamycin containing regimen, 100 mg of dexamethasone I V every 6 hours and 20 mg of oral thiethy- Iperazine were administered on the first day 20 mg of oral thiethylpyrazine only on the second and third day. The response rate was 73%, 73% on day 1,2 and 3, Side effects such as dizziness(64%), sedation(32%) and anxiety(37%) were observed, but relatively tolerable. We concluded that adequate combinations of antimetics according to cancer chemotherape- utic agents improve control of cancer chemotherapy-induced nausea and vomiting and treat- ment-related side effects.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2PI